Bioton S.A. - Asset Resilience Ratio
Bioton S.A. (BIO) has an Asset Resilience Ratio of 0.01% as of December 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bioton S.A. (BIO) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2019)
This chart shows how Bioton S.A.'s Asset Resilience Ratio has changed over time. See what is Bioton S.A.'s book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Bioton S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bioton S.A. market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł163.00K | 0.01% |
| Total Liquid Assets | zł163.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Bioton S.A. maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bioton S.A. Industry Peers by Asset Resilience Ratio
Compare Bioton S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Bioton S.A. (2005–2019)
The table below shows the annual Asset Resilience Ratio data for Bioton S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.20% | zł1.72 Million ≈ $474.19K |
zł881.42 Million ≈ $242.58 Million |
-2.28pp |
| 2016-12-31 | 2.47% | zł32.02 Million ≈ $8.81 Million |
zł1.30 Billion ≈ $356.45 Million |
+1.92pp |
| 2015-12-31 | 0.56% | zł6.95 Million ≈ $1.91 Million |
zł1.25 Billion ≈ $344.03 Million |
+0.53pp |
| 2013-12-31 | 0.03% | zł491.00K ≈ $135.13K |
zł1.89 Billion ≈ $520.37 Million |
-0.71pp |
| 2011-12-31 | 0.73% | zł14.83 Million ≈ $4.08 Million |
zł2.02 Billion ≈ $557.19 Million |
-0.87pp |
| 2010-12-31 | 1.61% | zł25.42 Million ≈ $7.00 Million |
zł1.58 Billion ≈ $435.30 Million |
+0.72pp |
| 2009-12-31 | 0.89% | zł14.32 Million ≈ $3.94 Million |
zł1.60 Billion ≈ $441.67 Million |
-1.35pp |
| 2008-12-31 | 2.24% | zł46.35 Million ≈ $12.76 Million |
zł2.06 Billion ≈ $568.26 Million |
+0.87pp |
| 2007-12-31 | 1.37% | zł21.23 Million ≈ $5.84 Million |
zł1.55 Billion ≈ $425.52 Million |
-5.08pp |
| 2006-12-31 | 6.46% | zł64.01 Million ≈ $17.62 Million |
zł991.63 Million ≈ $272.91 Million |
+6.00pp |
| 2005-12-31 | 0.46% | zł1.65 Million ≈ $452.73K |
zł358.12 Million ≈ $98.56 Million |
-- |
About Bioton S.A.
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes m… Read more